血管畸形的分子改变及其治疗靶点
本文综述血管畸形的分子遗传学进展,指出大多数血管畸形由体细胞镶嵌基因突变引起,主要涉及RAS/MAPK/ERK和PI3K/AKT/mTOR两条信号通路,并强调针对病因突变通路的靶向治疗前景。
要点
- 快流型动静脉畸形多与RAS/MAPK/ERK通路突变相关。
- 慢流型静脉和淋巴管畸形多与PI3K/AKT/mTOR通路突变相关。
- 靶向病因突变通路是血管畸形的新型治疗方向。
核心结论
- 血管畸形多由体细胞镶嵌基因突变所致,致病突变集中于RAS/MAPK/ERK和PI3K/AKT/mTOR两条信号通路,针对病因通路的靶向治疗是未来方向。
研究设计与样本
- 本文为综述,汇总反映更新版国际血管异常研究学会分类系统的现有文献,重点讨论潜在治疗靶点。
主要发现
- 快流型动静脉畸形通常涉及RAS/MAPK/ERK通路突变。
- 慢流型静脉和淋巴管畸形通常涉及PI3K/AKT/mTOR通路突变。
临床怎么用
- 血管外科医生应了解血管畸形的分子病因基础,以改善多学科协作。
- 靶向病因突变通路为血管畸形提供了新的治疗思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vascular anomalies are typically classified into two major categories, vascular tumors and vascular malformations. Most vascular malformations are caused sporadically by somatic mosaic gene mutations, and genetic analyses have advanced our understanding of the biomolecular mechanisms involved in their pathogenesis. Culprit gene mutations typically involve two major signaling pathways; the RAS/MAPK/ERK pathway is typically involved in fast-flow arteriovenous malformations, whereas the PI3K/AKT/mTOR pathway is typically mutated in slow-flow venous and lymphatic malformations. These findings suggest new therapeutic approaches to vascular malformations, focusing on targeting the etiologic mutated pathways. This review summarizes the currently available literature reflecting the updated International Society for Study of Vascular Anomalies classification system with emphasis on potential therapeutic targets that will provide vascular surgeons with an updated perspective on the etiologic basis of vascular malformations, allowing improved multidisciplinary collaboration.
引用
- Fereydooni A, Dardik A, Nassiri N, et al. Molecular changes associated with vascular malformations. J Vasc Surg. 2019. PMID: 30922748. doi:10.1016/j.jvs.2018.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。